PMID- 34650927
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220427
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After 
      Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small 
      Cell Lung Cancer.
PG  - 744956
LID - 10.3389/fonc.2021.744956 [doi]
LID - 744956
AB  - INTRODUCTION: For unresectable stage III non-small cell lung cancer (NSCLC), the 
      standard therapy consists of chemoradiotherapy (CRT) followed by durvalumab 
      maintenance for responding patients. The present study reports on the safety and 
      outcome of durvalumab use after CRT in a real-world, multicenter, retrospective 
      cohort. METHODS: Two hundred thirty-eight patients have been included. We 
      collected data on systemic therapy, radiation therapy, the timing between CRT and 
      durvalumab, number of durvalumab cycles, reasons for non-starting or 
      discontinuation, incidence and grade of adverse events (AEs), and 
      progression-free survival (PFS) and overall survival (OS). RESULTS: One hundred 
      fifty-five patients out of 238 (65.1%) received at least one durvalumab dose: 91 
      (58.7%) after concomitant CRT (cCRT) and 64 (41.3%) after sequential CRT (sCRT). 
      Programmed-death ligand 1 (PD-L1) status was unknown in 7/155 (4.5%), negative in 
      14 (9.1%), and positive >/=1% in 134/155 (86.4%). The main reasons for non-starting 
      durvalumab were progression (10.1%), PD-L1 negativity (7.5%), and lung toxicity 
      (4.6%). Median follow-up time was 14 months (range 2-29); 1-year PFS and OS were 
      65.5% (95%CI: 57.6-74.4) and 87.9% (95%CI: 82.26.6-93.9), respectively. No 
      significant differences in PFS or OS were detected for cCRT vs. sCRT, but the 
      median PFS was 13.5 months for sCRT vs. 23 months for cCRT. Potentially 
      immune-related AEs were recorded in 76/155 patients (49.0%). Pneumonitis was the 
      most frequent, leading to discontinuation in 11/155 patients (7.1%). CONCLUSIONS: 
      Durvalumab maintenenace after concurrent or sequential chemoradiation for 
      unresectable, stage III NSCLC showed very promising short-term survival results 
      in a large, multicenter, restrospective, real-world study. Durvalumab was the 
      first drug obtaining a survival benefit over CRT within the past two decades, and 
      the present study contributes to validating its use in clinical practice.
CI  - Copyright (c) 2021 Bruni, Scotti, Borghetti, Vagge, Cozzi, D'Angelo, Giaj Levra, 
      Fozza, Taraborrelli, Piperno, Vanoni, Sepulcri, Trovo, Nardone, Lattanzi, Bou 
      Selman, Bertolini, Franceschini, Agustoni, Jereczek-Fossa, Magrini, Livi, Lohr 
      and Filippi.
FAU - Bruni, Alessio
AU  - Bruni A
AD  - Radiotherapy Unit, Department of Oncology and Hematology, University Hospital of 
      Modena, Modena, Italy.
FAU - Scotti, Vieri
AU  - Scotti V
AD  - Department of Oncology, Radiation Therapy Unit, Careggi University Hospital, 
      Florence, Italy.
FAU - Borghetti, Paolo
AU  - Borghetti P
AD  - Radiation Oncology Department, Spedali Civili and University of Brescia, Brescia, 
      Italy.
FAU - Vagge, Stefano
AU  - Vagge S
AD  - Department of Radiation Oncology, Istituto di Ricovero e Cura a Carattere 
      Scientifico (IRCCS) Policlinico San Martino, Genova, Italy.
FAU - Cozzi, Salvatore
AU  - Cozzi S
AD  - Radiation Therapy Department, Arcispedale di Santa Maria Nuova IRCCS (Istituto di 
      Ricovero e Cura a Carattere Scientifico), Reggio Emilia, Italy.
FAU - D'Angelo, Elisa
AU  - D'Angelo E
AD  - Radiotherapy Unit, Department of Oncology and Hematology, University Hospital of 
      Modena, Modena, Italy.
FAU - Giaj Levra, Niccolo
AU  - Giaj Levra N
AD  - Advanced Radiation Oncology Department, Istituto di Ricovero e Cura a Carattere 
      Scientifico (IRCCS), Sacro Cuore Don Calabria Hospital, Verona, Italy.
FAU - Fozza, Alessandra
AU  - Fozza A
AD  - Department of Radiation Oncology, Istituto di Ricovero e Cura a Carattere 
      Scientifico (IRCCS) Policlinico San Martino, Genova, Italy.
FAU - Taraborrelli, Maria
AU  - Taraborrelli M
AD  - Radiation Oncology Department, SS. Annunziata Hospital, "G. D'Annunzio" 
      University of Chieti, Chieti, Italy.
FAU - Piperno, Gaia
AU  - Piperno G
AD  - Division of Radiotherapy, European Institute of Oncology (IEO), Istituto di 
      Ricovero e Cura a Carattere Scientifico (IRCCS) European Institute of Oncology, 
      Milan, Italy.
FAU - Vanoni, Valentina
AU  - Vanoni V
AD  - Radiation Oncology Department, S. Chiara Hospital, Trento, Italy.
FAU - Sepulcri, Matteo
AU  - Sepulcri M
AD  - Radiation Oncology Unit, Veneto Institute of Oncology Istituto Oncologico Veneto 
      (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy.
FAU - Trovo, Marco
AU  - Trovo M
AD  - Radiation Oncology Department, Azienda Sanitaria Universitaria Integrata, Udine, 
      Italy.
FAU - Nardone, Valerio
AU  - Nardone V
AD  - Radiotherapy Unit, "Ospedale del Mare", Naples, Italy.
FAU - Lattanzi, Elisabetta
AU  - Lattanzi E
AD  - Radiotherapy Unit, University Hospital of Parma, Parma, Italy.
FAU - Bou Selman, Said
AU  - Bou Selman S
AD  - Department of Radiotherapy, Bolzano Hospital, Bolzano, Italy.
FAU - Bertolini, Federica
AU  - Bertolini F
AD  - Medical Oncology Unit, Department of Oncology and Hematology, University Hospital 
      of Modena, Modena, Italy.
FAU - Franceschini, Davide
AU  - Franceschini D
AD  - Department of Radiotherapy and Radiosurgery, Humanitas Research Hospital, 
      Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Humanitas Research 
      Hospital, Milan, Italy.
FAU - Agustoni, Francesco
AU  - Agustoni F
AD  - Medical Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico 
      (IRCCS) Policlinico San Matteo, Pavia, Italy.
FAU - Jereczek-Fossa, Barbara Alicja
AU  - Jereczek-Fossa BA
AD  - Division of Radiotherapy, European Institute of Oncology (IEO), Istituto di 
      Ricovero e Cura a Carattere Scientifico (IRCCS) European Institute of Oncology, 
      Milan, Italy.
AD  - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
FAU - Magrini, Stefano Maria
AU  - Magrini SM
AD  - Radiation Oncology Department, Spedali Civili and University of Brescia, Brescia, 
      Italy.
FAU - Livi, Lorenzo
AU  - Livi L
AD  - Department of Oncology, Radiation Therapy Unit, Careggi University Hospital, 
      Florence, Italy.
FAU - Lohr, Frank
AU  - Lohr F
AD  - Radiotherapy Unit, Department of Oncology and Hematology, University Hospital of 
      Modena, Modena, Italy.
FAU - Filippi, Andrea Riccardo
AU  - Filippi AR
AD  - Department of Radiation Oncology, Fondazione Istituto di Ricovero e Cura a 
      Carattere Scientifico (IRCCS) Policlinico San Matteo and University of Pavia, 
      Pavia, Italy.
LA  - eng
PT  - Journal Article
DEP - 20210928
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
EIN - Front Oncol. 2021 Nov 16;11:802949. PMID: 34869046
PMC - PMC8507147
OTO - NOTNLM
OT  - *NSCLC
OT  - *chemoradiotherapy
OT  - *immunotherapy
OT  - *stage III
OT  - *unresectable
COIS- AB: speakers' bureau from Astra Zeneca, MSD, Tecnologie Avanzate; and advisory 
      role for Astra Zeneca. VS: speakers' bureau for Astra Zeneca, Roche, Accuray 
      Int.; and advisory role for Astra Zeneca. PB: speakers' bureau for Astra Zeneca. 
      SV: speakers' bureau for Astra Zeneca, Roche, Accuray Int. ED'A: speaker's bureau 
      from Nestle, MSD, Astra Zeneca; travel expenses: IPSEN; and expert testimony: 
      Nestle. NG: speakers' bureau for Astra Zeneca. DF: speakers' bureau for Astra 
      Zeneca; and advisory role for AstraZeneca. FA: speakers' bureau for Astra Zeneca, 
      Roche, BMS, Boehringer Ingelheim, MSD; and advisory role for Boehringer 
      Ingelheim, MSD. BJ-F: personal fees from Janssen, Roche, Astra Zeneca, and 
      Accuray, and institutional grants from AIRC, FIEO-CCM and Accuray Int., all 
      outside of the submitted work. ARF: speakers' bureau for Astra Zeneca, MSD, 
      Roche, Ipsen; advisory role for Astra Zeneca, Roche; institutional research 
      funding: Astra Zeneca; and honoraria for study conduction (not related to the 
      present study): Astra Zeneca. The remaining author declares that the research was 
      conducted in the absence of any commercial or financial relationships that could 
      be construed as a potential conflict of interest.
EDAT- 2021/10/16 06:00
MHDA- 2021/10/16 06:01
PMCR- 2021/01/01
CRDT- 2021/10/15 06:38
PHST- 2021/07/21 00:00 [received]
PHST- 2021/09/06 00:00 [accepted]
PHST- 2021/10/15 06:38 [entrez]
PHST- 2021/10/16 06:00 [pubmed]
PHST- 2021/10/16 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.744956 [doi]
PST - epublish
SO  - Front Oncol. 2021 Sep 28;11:744956. doi: 10.3389/fonc.2021.744956. eCollection 
      2021.